S86 Long-term assessment of exacerbations and lung function in the LIBERTY ASTHMA TRAVERSE study, stratified by lung function improvements at the end of the phase 3 LIBERTY ASTHMA QUEST parent study

Introduction and ObjectivesLow pre-bronchodilator FEV1 in asthma patients is associated with increased exacerbations and lung function decline. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation in multiple diseases. TRAVERSE (NCT02134028), a single-arm, open-label extension study, evaluated long-term safety, tolerability, and efficacy of dupilumab added to standard of care in adult/adolescent patients continuing from a previous dupilumab asthma study. Post-hoc analysis of TRAVERSE patients enrolled from QUEST (NCT02414854) with baseline blood eosinophils ≥150 cells/µL or FeNO ≥25 parts per billion assessed the relationship of lung function (characterized by baseline and change in pre-bronchodilator FEV1 and FEV1:forced vital capacity [FVC] ratio) on severe exacerbation rate (AER).MethodsPatients with increased type 2 inflammatory biomarkers who participated in QUEST (52 weeks) and continued to TRAVERSE (up to 96 weeks) were stratified by pre-bronchodilator FEV1 improvement at Week 52 of QUEST. Endpoints assessed were exacerbation history in the year before QUEST; annualized AER during QUEST and TRAVERSE; change from QUEST baseline in pre-bronchodilator FEV1 in QUEST and TRAVERSE and FEV1:FVC in TRAVERSE; and proportion of patients who maintained pre-bronchodilator FEV1 improvements at Week 52 in QUEST during TRAVERSE.ResultsOf 1,227 type 2 QUEST patients, 102 (8%) and 661 (54%) achieved